Basit öğe kaydını göster

dc.contributor.authorDoksat, Mehmet Kerem
dc.date.accessioned2021-03-05T21:03:03Z
dc.date.available2021-03-05T21:03:03Z
dc.date.issued2009
dc.identifier.citationDoksat M. K. , "Reversible Worsening of Psychosis Due to Benzydamine in a Schizoaffective Young Girl Who is Already Under Treatment with Antipsychotics", KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, cilt.19, ss.279-284, 2009
dc.identifier.issn1017-7833
dc.identifier.othervv_1032021
dc.identifier.otherav_d71560a2-ac31-45e0-ac19-c27eb86b18ae
dc.identifier.urihttp://hdl.handle.net/20.500.12627/141922
dc.description.abstractBenzydamine, available as the hydrochloride form, is an anti-inflammatory drug providing both rapid and extended pain relief in many painful inflammatory conditions, In oral dosages of 500 mg to 3000 mg it is a "deliriant" and CNS stimulant, popular in Poland and Brazil. In Brazil it is so popular that many people use it for recreational purposes. A person in a "benzydamine trip" may experience a feeling of well-being, euphoria and in higher doses hallucinations, paranoia, dry mouth and convulsions may also be experienced. In dosages of 750 mg to 2000-3000 mg benzydamine is a hallucinogen and CNS stimulant. These "triply" effects may be observed in poisoning or accidental or "on purpose" overdose cases also, hallucinosis (i.e. ego-dystonic hallucinations) is typical in such cases and generally remits spontaneously in 2 to 3 days after cessation of the drug even in children.
dc.language.isoeng
dc.subjectTemel Eczacılık Bilimleri
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.subjectSağlık Bilimleri
dc.subjectEczacılık
dc.subjectKlinik Tıp (MED)
dc.subjectPsikiyatri
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.titleReversible Worsening of Psychosis Due to Benzydamine in a Schizoaffective Young Girl Who is Already Under Treatment with Antipsychotics
dc.typeMakale
dc.relation.journalKLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY
dc.contributor.department, ,
dc.identifier.volume19
dc.identifier.issue3
dc.identifier.startpage279
dc.identifier.endpage284
dc.contributor.firstauthorID193128


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster